Compare · AVTX vs AZN
AVTX vs AZN
Side-by-side comparison of Avalo Therapeutics Inc. (AVTX) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTX and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $257.39B, about 242.0x AVTX ($1.06B).
- Over the past year, AVTX is up 106.5% and AZN is down 12.3% - AVTX leads by 118.9 points.
- Both names hit the wire about 12 times in the past 4 weeks.
- AZN has more recent analyst coverage (25 ratings vs 20 for AVTX).
- Company
- Avalo Therapeutics Inc.
- AstraZeneca PLC
- Price
- $19.41-2.24%
- $165.04-0.51%
- Market cap
- $1.06B
- $257.39B
- 1M return
- +5.23%
- -2.34%
- 1Y return
- +106.54%
- -12.35%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- 2026
- News (4w)
- 12
- 12
- Recent ratings
- 20
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AVTX
- Chief Financial Officer Sullivan Christopher Ryan sold $1,450,419 worth of shares (72,725 units at $19.94) as part of a pre-agreed trading plan and exercised 71,852 shares at a strike of $9.88, decreasing direct ownership by 2% to 39,900 units (SEC Form 4)
- Chief Medical Officer Doyle Mittie exercised 1,000 shares at a strike of $12.65 and sold $20,000 worth of shares (1,000 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.
- Chief Strategy Officer Riley Jennifer sold $52,012 worth of shares (2,655 units at $19.59), decreasing direct ownership by 7% to 37,041 units (SEC Form 4)
- Chief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $13,580 worth of shares (679 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.
- SEC Form 10-Q filed by Avalo Therapeutics Inc.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
- SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies